Andrew Van vurst

Chief Operating Officer, Biostem

Search every verified Andrew Van vurst interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Andrew VanVurst, Chief Operating Officer at BioStem Technologies, discussed the company's work in regenerative wound care in a September 2022 podcast appearance. He described BioStem's development of allograft products from perinatal tissue, including three approved products, and explained the regulatory distinctions between tissue allografts (361 products) and biologic drugs (351 products) under FDA guidance. VanVurst noted that tissue allografts, which involve transplanting human biologic tissue between individuals, are not held to the same clinical study requirements as biologic drugs because they do not claim to treat a specific condition. VanVurst also commented on the U.S. regulatory environment, stating that the FDA prioritizes product safety and efficacy for patients and has guided companies through specific pathways, citing the recent approval of CAR T therapies as an example. He and co-founder Jason Matuszewski highlighted their company's rapid path to commercial status, with in-house development and cGMP manufacturing facilities supporting their product portfolio.